Zinger Key Points
- Doximity's Q3 revenue rose 25% YoY to $168.6M, surpassing the $152.82M consensus. Adjusted EPS hit $0.45, beating estimates of $0.34.
- The company raised its FY25 revenue guidance to $564.6M–$565.6M, exceeding the prior outlook of $535M–$540M and the $539.98M consensus.
- Brand New Membership Level: Benzinga Trade Alerts
Doximity Inc DOCS stock is trading higher on Friday after the company reported third-quarter fiscal 2025 results that beat analysts’ expectations and upbeat guidance.
Doximity reported adjusted EPS of 45 cents, up from 29 cents a year ago and beating the consensus of 34 cents.
Sales increased 25% year-over-year to $168.6 million, beating the consensus of $152.82 million and management guidance of $152 million to $153 million.
Doximity offers a digital platform for U.S. medical professionals
“We’re proud to deliver another quarter of record engagement in Q3, with over 610,000 unique providers using our clinical workflow tools,” Doximity CEO Jeff Tangney said in a statement.
“Our AI tools grew the fastest last quarter, up 60% over the prior quarter, while our newsfeed surpassed more than one million unique providers.”
The company reported an adjusted EBITDA of $102.0 million, up 39% year over year, better than the management forecast of $83 million to $84 million. Net income jumped 57% to $75.2 million.
Guidance: For its fiscal fourth quarter, Doximity said it expects revenue of $132.5 million and $133.5 million, compared with analysts’ estimates of $123.84 million.
The company also raised its 2025 revenue guidance to $564.6 million—$565.6 million, up from the prior outlook of $535 million—$540 million and versus the consensus of $539.98 million.
Adjusted EBITDA is expected to be between $306.6 million and $307.6 million compared to prior guidance of $274 million to $279 million.
Analyst Reaction:
- Needham analyst Scott Berg maintains Doximity with a Buy and raises the price target from $65 to $82.
- Wells Fargo analyst Stan Berenshteyn maintains the company’s Equal-Weight rating and raises the price target from $43 to $55.
- Raymond James analyst Brian Peterson reiterates Doximity with an Outperform rating and raises the price target from $65 to $83.
Price Action: DOCS stock is up 37% at $79.80 at last check Friday.
Read Next:
Photo: courtesy of Doximity
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
